文献速递产科母胎医学

比较阿司匹林75至81毫克与150至162毫克预防早产型子痫前期:系统综述与荟萃分析

Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-05-04

该系统综述与荟萃分析纳入4项随机对照试验共552名参与者,比较妊娠早期开始每日阿司匹林150至162毫克与75至81毫克的预防效果。汇总分析显示,150至162毫克组早产型子痫前期风险显著降低(3项研究,472名参与者;RR 0.34;95%CI 0.15-0.79;P=.01;I²=0%),重度子痫前期也有所减少(RR 0.23;95%CI 0.09-0.62;P=.003;I²=0%)。作者结论认为,妊娠早期开始每日150至162毫克阿司匹林与较低的早产型子痫前期风险相关,但缺乏大型高质量研究限制了当前结果单独的临床适用范围。

要点

  • 妊娠早期开始每日阿司匹林150至162毫克较75至81毫克显著降低早产型子痫前期风险(RR 0.34;95%CI 0.15-0.79)。
  • 重度子痫前期风险也见减少(RR 0.23;95%CI 0.09-0.62;P=.003;I²=0%)。
  • 足月子痫前期和所有子痫前期风险无显著差异,且缺乏大型高质量研究限制临床适用范围。

核心结论

  • 妊娠早期开始每日阿司匹林150至162毫克与较低的早产型子痫前期风险相关,但缺乏大型高质量研究限制了当前结果单独的临床适用范围。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase、CINAHL、Web of Science和Cochrane Central Register of Controlled Trials从1985年1月至2023年4月。
  • 纳入比较妊娠早期开始两种阿司匹林剂量方案预防子痫前期的随机对照试验,干预为每日150至162毫克,对照为每日75至81毫克。
  • 共纳入4项随机对照试验,涉及552名参与者;2项试验偏倚风险不明确,1项低偏倚风险,1项高偏倚风险且未提供主要结局信息。
  • 2名评价者独立筛选文献、选择研究并评估偏倚风险,遵循PRISMA指南并使用Cochrane偏倚风险评估工具;联系通讯作者验证收集的结果。
  • 主要结局为早产型子痫前期风险,次要结局包括足月子痫前期、任何孕周子痫前期和重度子痫前期;计算相对危险度(RR)及95%置信区间(CI)并汇总分析。

主要发现

  • 阿司匹林150至162毫克组与75至81毫克组相比,早产型子痫前期风险显著降低(3项研究;472名参与者;RR 0.34;95%CI 0.15-0.79;P=.01;I²=0%)。
  • 足月子痫前期风险无显著差异(3项研究;472名参与者;RR 0.57;95%CI 0.12-2.64;P=.48;I²=64%)。
  • 任何孕周子痫前期风险无显著差异(4项研究;552名参与者;RR 0.42;95%CI 0.17-1.05;P=.06;I²=58%)。
  • 重度子痫前期风险降低(3项研究;472名参与者;RR 0.23;95%CI 0.09-0.62;P=.003;I²=0%)。

临床怎么用

  • 作者认为,妊娠早期开始每日阿司匹林150至162毫克与较低的早产型子痫前期风险相关,但缺乏大型高质量研究限制了当前结果单独的临床适用范围。

局限性

  • 缺乏大型高质量研究限制了当前结果单独的临床适用范围。
  • 2项随机对照试验偏倚风险不明确,1项高偏倚风险且未提供主要结局信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to compare 2 aspirin dosage regimens for the prevention of preterm preeclampsia (PE): 75 to 81 mg vs 150 to 162 mg taken daily starting in the first trimester of pregnancy. DATA SOURCES: A systematic search was performed using PubMed, Embase, CINAHL, Web of Science, and Cochrane Central Register of Controlled Trials from January 1985 to April 2023. STUDY ELIGIBILITY CRITERIA: The inclusion criteria were randomized controlled trials that compared the effect of 2 aspirin dosage regimens during pregnancy for the prevention of PE initiated in the first trimester of pregnancy. The intervention was an aspirin dosage between 150 and 162 mg daily, and the control was an aspirin dosage between 75 and 81 mg daily. METHODS: Of note, 2 reviewers independently screened all citations, selected studies, and evaluated the risk of bias. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and applied the Cochrane risk of bias tool. The corresponding authors of the included studies were contacted to validate each of the collected results. The primary outcome was the risk of preterm preeclampsia, and the secondary outcomes included term preeclampsia, any preeclampsia regardless of gestational age, and severe preeclampsia. Relative risks with their 95% confidence interval were calculated for each study and pooled for global analysis. RESULTS: Of note, 4 randomized controlled trials were retrieved involving 552 participants. Moreover, 2 randomized controlled trials were at unclear risk of bias, 1 trial at low risk of bias and 1 trial at high risk of bias, which did not have the information for the primary outcome. The pooled analysis demonstrated that an aspirin dosage of 150 to 162 mg was associated with a significant reduction of preterm preeclampsia, compared with an aspirin dosage of 75 to 81 mg (3 studies; 472 participants; relative risk, 0.34; 95% confidence interval, 0.15-0.79; P=.01; I2=0%). There was no significant effect on the risk of term preeclampsia (3 studies; 472 participants; relative risk, 0.57; 95% confidence interval, 0.12-2.64; P=.48; I2=64%) and all preeclampsia (4 studies; 552 participants; relative risk, 0.42; 95% confidence interval, 0.17-1.05; P=.06; I2=58%), but there was a reduction of severe preeclampsia (3 studies; 472 participantst; RR, 0.23; 95% CI, 0.09-0.62; P=.003; I2=0%). CONCLUSION: When initiated in the first trimester of pregnancy, an aspirin dosage of 150 to 162 mg daily was associated with a lower risk of preterm PE than an aspirin dosage of 75 to 81 mg daily. However, the lack of large, high-quality studies limited the clinical scope of the current results taken alone.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Ghesquiere L, Guerby P, Marchant I, et al. Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023. PMID: 37146687. doi:10.1016/j.ajogmf.2023.101000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。